newsfilter
← Latest News
GlobeNewswire·

Benitec Biopharma Releases Full Year 2026 Financial Results and Provides Operational Update

All six Cohort 1 (low dose BB-301) patients have completed the full 12-month post-treatment follow-up period, and Cohort 2 (high dose BB-301) is fully enrolled with all three patients having been safely treatedA Type C